ZA948031B - Methods of inhibiting uterine fibroses - Google Patents
Methods of inhibiting uterine fibrosesInfo
- Publication number
- ZA948031B ZA948031B ZA948031A ZA948031A ZA948031B ZA 948031 B ZA948031 B ZA 948031B ZA 948031 A ZA948031 A ZA 948031A ZA 948031 A ZA948031 A ZA 948031A ZA 948031 B ZA948031 B ZA 948031B
- Authority
- ZA
- South Africa
- Prior art keywords
- fibroses
- methods
- chem
- inhibiting uterine
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/138,642 US5457116A (en) | 1993-10-15 | 1993-10-15 | Methods of inhibiting uterine fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA948031B true ZA948031B (en) | 1996-04-15 |
Family
ID=22482959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA948031A ZA948031B (en) | 1993-10-15 | 1994-10-13 | Methods of inhibiting uterine fibroses |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5457116A (xx) |
| EP (1) | EP0651999B1 (xx) |
| JP (1) | JPH07188015A (xx) |
| KR (1) | KR950010892A (xx) |
| CN (1) | CN1058389C (xx) |
| AT (1) | ATE216582T1 (xx) |
| AU (1) | AU680042B2 (xx) |
| CA (1) | CA2118090A1 (xx) |
| CZ (1) | CZ287247B6 (xx) |
| DE (1) | DE69430465T2 (xx) |
| DK (1) | DK0651999T3 (xx) |
| ES (1) | ES2172525T3 (xx) |
| HU (1) | HUT71236A (xx) |
| IL (1) | IL111285A (xx) |
| NO (1) | NO943878L (xx) |
| NZ (1) | NZ264678A (xx) |
| PH (1) | PH31596A (xx) |
| PT (1) | PT651999E (xx) |
| RU (1) | RU2145851C1 (xx) |
| SG (1) | SG46324A1 (xx) |
| TW (1) | TW327601B (xx) |
| UA (1) | UA27883C2 (xx) |
| ZA (1) | ZA948031B (xx) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| USRE39049E1 (en) | 1992-07-28 | 2006-03-28 | Eli Lilly And Company | Methods for inhibiting bone loss |
| USRE38968E1 (en) | 1992-07-28 | 2006-02-07 | Eli Lilly And Company | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
| CA2162586C (en) | 1993-05-13 | 2006-01-03 | David J. Grainger | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
| US5856340A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
| CA2223595C (en) | 1995-06-07 | 2008-08-05 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
| CZ235398A3 (cs) * | 1996-01-29 | 1999-02-17 | Eli Lilly And Company | Farmaceutický prostředek pro inhibici muskuloaponeurotických fibromatóz savců zvláště lidí |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| US5670523A (en) * | 1996-01-29 | 1997-09-23 | Eli Lilly And Company | Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors) |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| US5827876A (en) * | 1996-04-09 | 1998-10-27 | American Home Products Corporation | Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| ATE321754T1 (de) * | 2001-05-22 | 2006-04-15 | Lilly Co Eli | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren |
| JP2004531559A (ja) * | 2001-05-22 | 2004-10-14 | イーライ・リリー・アンド・カンパニー | エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体 |
| US20060106010A1 (en) * | 2003-05-27 | 2006-05-18 | Black Larry J | Methods for inhibiting bone loss |
| US20080221163A1 (en) * | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| DE4122484A1 (de) * | 1991-07-06 | 1993-01-07 | Teves Gmbh Alfred | Schaltungsanordnung zur erkennung von radsensordefekten |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| US5461065A (en) * | 1993-10-15 | 1995-10-24 | Eli Lilly And Company | Methods for inhibiting endometriosis |
| US5418252A (en) * | 1993-10-15 | 1995-05-23 | Eli Lilly And Company | Method for inhibiting cartilage degradation |
| US5457113A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
-
1993
- 1993-10-15 US US08/138,642 patent/US5457116A/en not_active Expired - Lifetime
-
1994
- 1994-10-12 UA UA94105916A patent/UA27883C2/uk unknown
- 1994-10-13 JP JP6247768A patent/JPH07188015A/ja not_active Ceased
- 1994-10-13 DK DK94307521T patent/DK0651999T3/da active
- 1994-10-13 ZA ZA948031A patent/ZA948031B/xx unknown
- 1994-10-13 EP EP94307521A patent/EP0651999B1/en not_active Expired - Lifetime
- 1994-10-13 CA CA002118090A patent/CA2118090A1/en not_active Abandoned
- 1994-10-13 HU HU9402960A patent/HUT71236A/hu unknown
- 1994-10-13 NZ NZ264678A patent/NZ264678A/en unknown
- 1994-10-13 IL IL11128594A patent/IL111285A/en not_active IP Right Cessation
- 1994-10-13 NO NO943878A patent/NO943878L/no not_active Application Discontinuation
- 1994-10-13 SG SG1996002922A patent/SG46324A1/en unknown
- 1994-10-13 CZ CZ19942538A patent/CZ287247B6/cs not_active IP Right Cessation
- 1994-10-13 ES ES94307521T patent/ES2172525T3/es not_active Expired - Lifetime
- 1994-10-13 PH PH49187A patent/PH31596A/en unknown
- 1994-10-13 RU RU94037235A patent/RU2145851C1/ru active
- 1994-10-13 PT PT94307521T patent/PT651999E/pt unknown
- 1994-10-13 TW TW083109468A patent/TW327601B/zh active
- 1994-10-13 CN CN94117126A patent/CN1058389C/zh not_active Expired - Fee Related
- 1994-10-13 DE DE69430465T patent/DE69430465T2/de not_active Expired - Fee Related
- 1994-10-13 AT AT94307521T patent/ATE216582T1/de not_active IP Right Cessation
- 1994-10-13 KR KR1019940026163A patent/KR950010892A/ko not_active Application Discontinuation
- 1994-10-14 AU AU75834/94A patent/AU680042B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| HUT71236A (en) | 1995-11-28 |
| JPH07188015A (ja) | 1995-07-25 |
| CA2118090A1 (en) | 1995-04-16 |
| DE69430465D1 (de) | 2002-05-29 |
| ATE216582T1 (de) | 2002-05-15 |
| AU680042B2 (en) | 1997-07-17 |
| HU9402960D0 (en) | 1995-02-28 |
| KR950010892A (ko) | 1995-05-15 |
| CN1058389C (zh) | 2000-11-15 |
| SG46324A1 (en) | 1998-02-20 |
| ES2172525T3 (es) | 2002-10-01 |
| IL111285A (en) | 1998-12-27 |
| CN1107156A (zh) | 1995-08-23 |
| EP0651999A1 (en) | 1995-05-10 |
| UA27883C2 (uk) | 2000-10-16 |
| IL111285A0 (en) | 1994-12-29 |
| CZ287247B6 (en) | 2000-10-11 |
| EP0651999B1 (en) | 2002-04-24 |
| CZ253894A3 (en) | 1995-05-17 |
| NZ264678A (en) | 1997-07-27 |
| NO943878D0 (no) | 1994-10-13 |
| DE69430465T2 (de) | 2002-10-31 |
| RU2145851C1 (ru) | 2000-02-27 |
| US5457116A (en) | 1995-10-10 |
| DK0651999T3 (da) | 2002-06-17 |
| NO943878L (no) | 1995-04-18 |
| RU94037235A (ru) | 1996-11-10 |
| TW327601B (en) | 1998-03-01 |
| AU7583494A (en) | 1995-05-04 |
| PH31596A (en) | 1998-11-03 |
| PT651999E (pt) | 2002-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA948031B (en) | Methods of inhibiting uterine fibroses | |
| ZA9410084B (en) | Methods of inhibiting thrombin | |
| SI0652005T1 (en) | Methods for inhibiting endometriosis | |
| IL112042A0 (en) | Methods of inhibiting seborrhea and acne | |
| ZA948028B (en) | Methods for inhibiting cartilage degradation | |
| HU9403663D0 (en) | Methods of inhibiting dysfunctional uterine bleeding | |
| AU7578694A (en) | Methods for treating resistant neoplasms | |
| ZA948027B (en) | Methods for inhibiting angiogenesis and angiogenic diseases | |
| HU9403665D0 (en) | Methods of inhibiting hirsutism and alopecia in women |